Update on recent developments for patients with newly diagnosed multiple myeloma.
Recent studies have demonstrated that novel therapeutic combinations are challenging melphalan and prednisone (MP) as the standard of care in elderly patients with multiple myeloma. Combination regimens containing bortezomib or thalidomide can achieve response rates, especially complete response rates, which are superior to those seen with standard MP alone, and offer new possibilities for this patient population.
Palumbo
Antonio
A
Divisione di Ematologia dell'Università di Torino, Torino, Italy. appalumbo@yahoo.com
Magarotto
Valeria
V
Gay
Francesca
F
Falco
Patrizia
P
Bringhen
Sara
S
Boccadoro
Mario
M
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001897:Boronic Acids / Q000008:administration & dosage; D000069286:Bortezomib; D006801:Humans; D008558:Melphalan / Q000008:administration & dosage; D009101:Multiple Myeloma / Q000188:drug therapy*; D011241:Prednisone / Q000008:administration & dosage; D011719:Pyrazines / Q000008:administration & dosage; D013792:Thalidomide / Q000008:administration & dosage; D016896:Treatment Outcome
D001897:Boronic Acids; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib; D008558:Melphalan; D011241:Prednisone